KYNMOBI
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $168.88 | 8 | 8 |
| 2022 | $49,763 | 3,303 | 1,328 |
| 2021 | $631,185 | 10,724 | 2,905 |
| 2020 | $332,617 | 2,259 | 1,125 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $382,928 | 260 | 37.8% |
| Unspecified | $324,990 | 72 | 32.1% |
| Food and Beverage | $248,201 | 15,897 | 24.5% |
| Consulting Fee | $49,332 | 21 | 4.9% |
| Space rental or facility fees (teaching hospital only) | $5,000 | 1 | 0.5% |
| Travel and Lodging | $2,133 | 14 | 0.2% |
| Education | $1,150 | 29 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | Sunovion Pharmaceuticals Inc. | $303,346 | 0 |
| Dasotraline Binge Eating Disorder Extension Study | Sunovion Pharmaceuticals Inc. | $21,644 | 0 |
Top Doctors Receiving Payments for KYNMOBI — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Fernando Pagan | Neurology | Washington, DC | $2,966 | 29 |
| , MD | Neurology | Oklahoma City, OK | $2,812 | 33 |
| , MD | Geriatric Medicine | Haworth, NJ | $2,800 | 2 |
| , M.D | Neurology | Houston, TX | $2,767 | 19 |
| , D.O | Neurology | Coconut Creek, FL | $2,650 | 35 |
| , M.D | Neurology | Scottsdale, AZ | $2,607 | 11 |
| , D.O | Neurology | Salt Lake City, UT | $2,569 | 7 |
| , M.D | Neurology | Toledo, OH | $2,512 | 2 |
| , M.D | Neurology | Los Angeles, CA | $2,500 | 1 |
| , M.D., J.D | Neurology | Philadelphia, PA | $2,500 | 1 |
| , D.O | Neurology | Tampa, FL | $2,381 | 3 |
| , MD | Neurology | Wakefield, RI | $2,271 | 12 |
| , MD | Neurology | Los Angeles, CA | $2,250 | 1 |
| , M.D | Neurology | Phoenix, AZ | $2,161 | 12 |
| , MD | Neurology | Pasadena, CA | $2,157 | 8 |
| , MD | Neurology | Boynton Beach, FL | $2,089 | 2 |
| , D.O | Neurological Surgery | Sacramento, CA | $2,075 | 1 |
| , M.D | Psychiatry | Huntersville, NC | $2,050 | 1 |
| , DO | Vascular Neurology | Ocala, FL | $1,863 | 15 |
| , M.D | Neurology | Carlsbad, CA | $1,805 | 35 |
| , MD | Neurology | Cleveland, OH | $1,618 | 1 |
| , DMD | Oral & Maxillofacial Surgery | Radnor, PA | $1,600 | 1 |
| , MD | Internal Medicine | North Easton, MA | $1,600 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Albuquerque, NM | $1,600 | 1 |
| , M.D | Neurology | Newark, DE | $1,341 | 7 |
Manufacturing Companies
- Sunovion Pharmaceuticals Inc. $1.0M
- Sumitomo Pharma America, Inc. $168.88
Product Information
- Type Drug
- Total Payments $1.0M
- Total Doctors 3,762
- Transactions 16,294
About KYNMOBI
KYNMOBI is a drug associated with $1.0M in payments to 3,762 healthcare providers, recorded across 16,294 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2020 to 2023. In 2023, $168.88 was paid across 8 transactions to 8 doctors.
The most common payment nature for KYNMOBI is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($382,928, 37.8% of total).
KYNMOBI is associated with 2 research studies, including "Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease" ($303,346).